[{"NetIncomeLoss_1_Q3_USD":-14631000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q3_shares":24449115.0,"IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_3_Q3_USD":-1.67,"IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_1_Q3_USD":-0.6,"CommitmentsAndContingencies_0_Q3_USD":null,"GainLossOnSaleOfPropertyPlantEquipment_3_Q3_USD":0.0,"AccruedLiabilitiesCurrent_0_Q3_USD":5669000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q3_USD":74000.0,"NetCashProvidedByUsedInInvestingActivities_3_Q3_USD":-102930000.0,"WeightedAverageNumberOfSharesIssuedBasic_3_Q3_shares":24019746.0,"WeightedAverageNumberOfSharesIssuedBasic_1_Q3_shares":24474157.0,"AssetsCurrent_0_Q3_USD":125508000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3_Q3_shares":1614295.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q3_USD":165000.0,"StockIssuedDuringPeriodValueShareBasedCompensation_1_Q3_USD":2005000.0,"AvailableForSaleSecuritiesDebtSecurities_0_Q3_USD":121645000.0,"Assets_0_Q3_USD":128970000.0,"ShareBasedCompensation_3_Q3_USD":6128000.0,"CommonStockCapitalSharesReservedForFutureIssuance_0_Q3_shares":4195291.0,"ProceedsFromIssuanceOfCommonStock_3_Q3_USD":69842000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3_Q3_shares":23989926.0,"GeneralAndAdministrativeExpense_1_Q3_USD":3197000.0,"GeneralAndAdministrativeExpense_3_Q3_USD":9288000.0,"DepreciationAndAmortization_3_Q3_USD":858000.0,"ResearchAndDevelopmentExpense_1_Q3_USD":12912000.0,"ProceedsFromStockPlans_3_Q3_USD":411000.0,"IncomeTaxExpenseBenefit_3_Q3_USD":791000.0,"IncomeTaxExpenseBenefit_1_Q3_USD":287000.0,"IncreaseDecreaseInDeferredRevenue_3_Q3_USD":2260000.0,"CommonStockValue_0_Q3_USD":2000.0,"IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_3_Q3_USD":5207000.0,"ForeignCurrencyTransactionGainLossBeforeTax_3_Q3_USD":65000.0,"NetCashProvidedByUsedInFinancingActivities_3_Q3_USD":70901000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_3_Q3_USD":3740000.0,"ProceedsFromSaleAndMaturityOfMarketableSecurities_3_Q3_USD":20000000.0,"ComprehensiveIncomeNetOfTax_3_Q3_USD":-40103000.0,"ComprehensiveIncomeNetOfTax_1_Q3_USD":-14734000.0,"OtherAssetsNoncurrent_0_Q3_USD":389000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q3_USD":20229000.0,"AdditionalPaidInCapitalCommonStock_0_Q3_USD":312078000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_3_Q3_USD":119000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q3_USD":-33000.0,"MarketableSecuritiesCurrent_0_Q3_USD":102557000.0,"DepreciationAndAmortization_1_Q3_USD":300000.0,"DeferredRevenueNoncurrent_0_Q3_USD":1132000.0,"ResearchAndDevelopmentExpense_3_Q3_USD":34581000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q3_USD":1528000.0,"WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_1_Q3_shares":25042.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3_Q3_USD":-39366000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q3_USD":-14344000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_3_Q3_USD":-65000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1_Q3_USD":-70000.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-25125000.0,"WorkersCompensationLiabilityCurrent_0_Q3_USD":3156000.0,"LiabilitiesCurrent_0_Q3_USD":15591000.0,"DeferredRevenueCurrent_0_Q3_USD":5128000.0,"AccountsPayableCurrent_0_Q3_USD":4405000.0,"NonoperatingIncomeExpense_3_Q3_USD":763000.0,"NonoperatingIncomeExpense_1_Q3_USD":237000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q3_USD":2722000.0,"ProceedsFromStockOptionsExercised_3_Q3_USD":648000.0,"OtherAccruedLiabilitiesCurrent_0_Q3_USD":60000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0_Q3_USD":20229000.0,"DividendsCommonStock_3_Q3_USD":0.0,"ProceedsFromIssuanceOfConvertiblePreferredStock_3_Q3_USD":0.0,"PropertyPlantAndEquipmentNet_0_Q3_USD":3073000.0,"NetIncomeLoss_3_Q3_USD":-40157000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q3_USD":119000.0,"AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0_Q3_USD":6866000.0,"PaymentsToAcquireMarketableSecurities_3_Q3_USD":122706000.0,"CommonStockSharesOutstanding_0_Q3_shares":24495525.0,"OperatingIncomeLoss_3_Q3_USD":-40129000.0,"OperatingIncomeLoss_1_Q3_USD":-14581000.0,"InvestmentIncomeAmortizationOfPremium_3_Q3_USD":268000.0,"PreferredStockValue_0_Q3_USD":null,"LiabilitiesAndStockholdersEquity_0_Q3_USD":128970000.0,"AllocatedShareBasedCompensationExpense_3_Q3_USD":6128000.0,"AllocatedShareBasedCompensationExpense_1_Q3_USD":2005000.0,"PropertyPlantAndEquipmentGross_0_Q3_USD":9939000.0,"OperatingExpenses_3_Q3_USD":43869000.0,"WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_3_Q3_shares":29820.0,"OperatingExpenses_1_Q3_USD":16109000.0,"EarningsPerShareBasicAndDiluted_1_Q3_USD":-0.6,"ProfitLoss_3_Q3_USD":-40157000.0,"OtherLiabilitiesCurrent_0_Q3_USD":389000.0,"StockholdersEquity_0_Q3_USD":110047000.0,"PaymentsToAcquirePropertyPlantAndEquipment_3_Q3_USD":224000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q3_USD":121526000.0,"DeferredRentCreditNoncurrent_0_Q3_USD":2200000.0,"RetainedEarningsAccumulatedDeficit_0_Q3_USD":-202107000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3_Q3_USD":-57154000.0,"EarningsPerShareBasicAndDiluted_3_Q3_USD":-1.67,"AccruedProfessionalFeesCurrent_0_Q3_USD":270000.0,"Ticker":"RAPT","CIK":"1673772","name":"RAPT THERAPEUTICS, INC.","OfficialName":"RAPT Therapeutics Inc. Common Stock","form":"10-Q","period":"20200930","fy":"2020.0","fp":"Q3","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"595076458.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20201116"}]